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Background: Transcription activator-like effector nucleases (TALENs) are a useful tool for targeted gene editing. TALEN
monomers are traditionally expressed from two different plasmids. Each encodes a different TALEN arm that binds to a
user-defined sequence and mediates gene editing. Expression of TALEN monomers in two separate plasmids requires
co-delivery of each plasmid to the cell. Efficacy of gene editing may be increased if each monomer was transcribed
from the same reading frame.
Findings: We developed a TALEN scaffold which expresses both TALEN monomers from a single open reading frame
in equal molar amount by linking both monomers with a 2A self-cleaving peptide sequence. This TALEN scaffold,
named pTAL10, demonstrates higher levels of genome editing than co-transfected TALENs at similar levels of
transfection efficiencies when analyzed for TALEN-induced small insertions and deletions.
Conclusions: This protocol for gene editing using 2A-linked TALENs requires transfection of only one plasmid as
compared to transfection of two separate plasmids encoding each TALEN monomers.
Keywords: Gene editing, TALEN, 2A self-cleaving sequenceFindings
Background
Transcription activator-like effector nucleases (TALENs)
are an exciting gene-editing tool that has emerged in
recent years. Their DNA-binding domains are based
on transcription activator-like effector (TALE) proteins
from Xanthomonas plant pathogens [1-4]. The central
repeat domain in the TALE structure mediates DNA
binding with each repeat specifying one target base. The
base preference of each repeat is determined by two
critical, adjacent amino acids referred to as the “repeat
variable di-residue” (RVD) which preferentially recog-
nizes one of the four bases in the target site [5,6]. This
simple “two amino acids for one base” code enables
rapid engineering of customized TALE repeat arrays that
recognize a user-defined target sequence. Using default
settings for TAL Effector Nucleotide Targeter 2.0 [7],
one can identify a unique TALE-binding site for every
nucleotide of target sequence—this frequency makes it a
highly attractive gene editing tool. Indeed, TALEN has* Correspondence: renzhi.han@osumc.edu
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unless otherwise stated.been used to modify genes in a number of different cell
types and organisms with low off-target activity [8].
Several approaches have been taken to improve the
specificity and efficiency of TALEN, including modifi-
cation of FokI cleavage domain [9,10], N-terminal and
C-terminal segments flanking central repeat domains
[11], and enrichment of edited cells by using fluorescence
activated cell sorting (FACS) [12]. Two TALEN mono-
mers are required to induce a double strand break in the
genomic DNA of the cells, thus requiring co-delivery of
both TALEN monomers into the target cells. To reduce
the complication associated with co-transfection by
which a portion of cells are only singly transfected,
we previously [13] demonstrated that two functional
TALEN monomers can be expressed from a single tran-
script by the use of a self-cleaving 2A peptide derived
from equine rhinitis A virus (E2A; QCTNYALLKLAGD
VESNPGP) or Thosea asigna virus (T2A; EGRGSLLT
CGDVEENPGP) [14,15]. Upon translation, the ribo-
some skips the synthesis of the glycyl-prolyl peptide
bond between the ending glycine and proline of the 2A
sequence, resulting in the release of the antecedent pro-
tein and the re-initiation of translation of the following
proline amino acid [16]. This strategy ensures that eachl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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equal molar amount, ultimately displaying higher gene
editing efficiencies.
In the present study, we compared the gene editing per-
formances of previously constructed TALENs targeting
two different loci: MSTN [13] and AAVS1 locus [3]. Add-
itionally, we provided a protocol that can help guide con-
struction of a functional TALEN using pTAL10 scaffold.
Results and discussion
We quantitatively compared the gene editing perform-
ance of our previously characterized TALENs targeting
myostatin [13] expressed in one plasmid with the same
TALENs expressed in two separate plasmids. HEK293
cells were transfected with either mock, co-transfection
(myostatin TALEN left and right monomers in two
separate plasmids), or pTAL10-MSTN (two TALEN
monomers in one plasmid) (Figure 1). Western blotting
showed that the TALEN monomers (~110 kDa) were
faithfully expressed from either the two separate plas-
mids (each TALEN monomer is fused with a 3×FLAG tag)
or the single plasmid linked by a T2A sequence (right
TALEN monomer is fused with a 2×HA tag, whereas the
left monomer is fused with a 3×FLAG tag) (Figure 2a).
Consistent with previous reports that T2A mediates high
self-cleavage efficiency [15], only a very small fraction
of the 220 kDa full-length precursor protein was visible
with a high exposure time (Figure 2a). Gene editing
activity was quantified by the mismatch-sensitive T7
endonuclease I (T7E1) assay which detects the TALEN-
induced insertions and deletions (indels) around the
target site (Figure 2b and c). TALENs expressed from
one single plasmid exhibited higher gene editing activity
than co-transfection of two TALEN monomers under
the same conditions (Figure 2b and c).
To test whether the improved gene editing activity is
MSTN specific, we constructed another previously char-
acterized TALENs targeting human AAVS1 locus [17].
Again, the AAVS1-TALEN monomers were faithfullyFigure 1 Cartoon of relevant domains for TALEN-L (left), TALEN-R (rig
AAVS1 locus targeting TALEN constructs (TALEN-L, TALEN-R, and pTAL10-TALE
EGFP/3xFLAG or mCherry/3xFLAG for transfection and biochemical monitorin
a self-peptide cleaving sequence. Left and right monomers can be fluorescen
tags respectively.expressed and properly cleaved using the pTAL10 scaf-
fold (Figure 2d). T7E1 assay showed that AAVS1
TALENs expressed from the one-plasmid pTAL10 in-
duced higher gene editing activity than the two sepa-
rated plasmid system (Figure 2e and f).
To facilitate the assembly of two TALEN monomers
into one plasmid, we constructed a TALEN scaffold desig-
nated as pTAL10 (Figure 3), wherein two TALEN mono-
mers (left and right) can be sequentially assembled in a
similar way as previously described [4] with some modifi-
cations. After assembly of user-defined RVD sequences in
their respective pFUS backbone, these RVD sequences
and last repeat sequence (pLR-X, where X represents
RVD) can be ligated to the left TALEN scaffold of pTAL10
upon digestion with BsmBI (Figure 3, Step 1). To
complete construction, Golden Gate assembly is repeated
on the pTAL10 containing assembled left TALEN for the
right monomer. Different from the previous reaction, this
digestion includes both BsmBI and BsaI for unveiling
appropriate sticky-ends (Figure 3, Step 2). Each TALEN
monomer scaffold is based on the GoldyTALEN [18]
which has increased gene editing efficiency.
In order to detect expression of each monomer
uniquely by western blotting analysis, each monomer
is fused with a tag at its N-terminal: 3xFLAG for left
TALEN monomer, and 2xHA for the right. In addition,
the TALEN monomer scaffold uses the obligate heterodi-
meric FokI variants (ELD-sharkey or KKR-sharkey) [13].
The two monomers and GFP (used as a reporter for
transfection) are linked by the aforementioned Thosea
asigna and equine rhinitis A virus 2A peptide sequences,
respectively. We removed all BsaI and BsmBI sites out-
side of the TALEN scaffold in the final pTAL10 plasmid
using site-directed mutagenesis so that it is fully compat-
ible with the Golden Gate platform [4]. The map and
sequence of pTAL10 as well as a detailed step-by-
step protocol to assemble the TALEN monomers into
this single TALEN scaffold plasmid are provided in the
supplement (Additional files 1 and 2).ht), and pTAL10-TALEN. Diagram of notable regions of myostatin or
N) and experimental design. Monomers TALEN-L and TALEN-R contain
g respectively. pTAL10-TALEN contains both TALEN monomers, linked by
tly or biochemically monitored by EGFP/3xFLAG or mCherry/2xHA
Figure 2 T2A-linked TALENs demonstrate increased gene editing activity than co-transfected TALEN monomers. (a, d) Western blotting
shows proper expression of co-transfected TALENs, tagged with 3xFLAG sequence, or pTAL10-TALENs, tagged with 2xHA/3xFLAG sequences,
targeting MSTN or AAVS1 respectively. Asterisk (*) depicts uncleaved TALENs arms or GFP-TALEN. GAPDH was used as a loading control. (b, e)
Representative gel of T7E1 assay comparing gene editing activities of co-transfected TALENs and T2A-linked TALENs targeting MSTN or AAVS1
respectively. Upper band, demarcated with an arrow, represents noncleaved DNA; bottom bands, demarcated with an arrow head, represent cleaved DNA
fragments. Image is representative of 4–6 biological replicates. (c, f) Cleavage activity of TALEN (TALEN-L/R co-transfection vs. pTAL10-TALEN) targeting MSTN or
AAVS1 respectively were compared using T7E1 endonuclease assay. Results are from 4–6 biological replicates. p<0.05 was considered to be significant.
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We have generated an improved TALEN scaffold, desig-
nated as pTAL10, by utilizing a self-cleaving peptide
sequence. pTAL10 demonstrates higher gene editing
when compared to co-transfected TALEN-L and R due
to proper co-delivery of TALE monomers. Additionally,
this improved scaffold allows transfection efficiency toFigure 3 Schematic of sequential assembly of TALE repeats into pTAL
nuclease scaffolds denoted as “left” and “right”. TALE repeats are assembled
BsaI/BsmBI restriction enzymes, respectively. The scaffold also contains kanam
cassette for selection in mammalian cells. The listed restriction sites are: N, Nhbe fluorescently monitored, while expression of each
TALEN arm to be biochemically monitored.
Methods
Creation of TALE nucleases
Construction of AAVS1-L, AAVS1-R, MSTN-L, and
MSTN-R for co-transfection was previously described10. pTAL10 is comprised of GFP (transfection reporter) and two TALE
into the left and right scaffolds sequentially by the use of BsmBI and
ycin-resistant cassette for selection in bacteria and neomycin- resistant
eI; K, KpnI; B, BglII; X, XhoI.
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creation of pTAL10-AAVS1 and pTAL10-MSTN, respect-
ively, was constructed using Golden Gate TALEN Kit 2.0
(Kit #1000000024) from Addgene. These sequences were
then added to pTAL10 (Figure 2) by using BsmBI and
BsmBI/BsaI digestion respectively. Further details on cre-
ation of TALE nucleases using pTAL10 scaffold is dis-
cussed below and in the supplemental protocol.
Cell culture and transfection
HEK293 cells were cultured in DMEM supplemented with
10% FBS, 1% L-glutamine (Thermo Scientific Hyclone,
Waltham, MA), and 1% Penicillin-Streptomycin (Thermo
Scientific Hyclone, Waltham, MA). Transient transfection by
Xfect transfection reagent (Clontech, Mountain View, CA)
was done according to manufacturer’s recommendation. In
short, HEK293 cells for each downstream application (gen-
omic DNA or protein extraction) were seeded in a 6-well
plate until 60-70% confluency. Thereafter, 5 μg of total DNA
(pTAL10-TALEN single plasmid transfection, or TALEN-L/
TALEN-R co-transfection) in nanoparticle complex solution
was added to the culture medium dropwise, followed by re-
placement of medium 16–20 hours post transfection. After
72 hours, either genomic DNA or protein was extracted
from these cell lines. Transfection efficiency was determined
by fluorescence microscopy analysis: 1) the average percent-
age of mCherry- or GFP-positive cells for co-transfection or
2) the percentage of GFP-positive cells for pTAL10-TALENs.
Western blot
HEK293 transfected with single pTAL10-MSTN or co-
transfection with MSTN-L and MSTN-R were lysed 48–
72 hours post transfection with cold RIPA buffer supple-
mented with protease inhibitors (1 mM PMSF and 1 mM
Benzamidine). Protein concentration was determined by
using Bradford Protein Assay Kit (IBI Scientific, Peosta,
IA). 20 μg of protein were resolved on a 4-20% Mini-
PROTEAN TGX Precast Gel (Bio-Rad Laboratories,
Hercules, CA) and transferred onto a PVDF mem-
brane (Millipore, Billerica, MA). Immunoblotting was
done with the following antibodies: mouse monoclonal
anti-FLAG (F3165; Sigma-Aldrich, Saint Louis, MO),
polyclonal anti-HA-Tag antibody (Clontech, Mountain
View, CA), mouse monoclonal anti-GAPDH (Millipore,
Billerica, MA), and HRP conjugated goat anti-mouse IgG
(Millipore, Billerica, MA). Membranes were developed using
ECL 2 Western Blotting Substrate (Pierce Biotechnology,
Rockford, IL) and images were captured using ChemiDoc
XRS + system (Bio-Rad Laboratories, Hercules, CA).
T7E1 mismatch-detection assay
Cleavage activity of AAVS1 and MSTN TALENs, as mea-
sured by small deletion/insertion mutations (indels), were
quantified by mismatch-recognizing T7E1 as describedpreviously [13]. Briefly, cells transfected with respect-
ive TALENs had genomic DNA extracted 48–72 hours
post-transfection. Amplification was achieved by using
AccuPrime Pfx (Invitrogen, Carlsbad, CA). PCR primers
were designed to amplify site surrounding human AAVS1
or human MSTN locus. Specifically, the primer pair
for human MSTN binds to Intron 1–2 (hGDF8-F1, 5′-
TGGAGGGGTTTTGTTAATGG-3′) and Intron 2–3
(hGDF8-F2, 5′-TATTGGGTACAGGGCTACCG-3′). The
primer pair used for AAVS1 targets the following
sites: AS1L-833 F (5′- TTCAGGTTCCGTCTTCCTC
CACTC – 3′) and AS1l-1998R (5′- AACTGACGCA
CGGAGGAACAAT-3′). The DNA fragment was purified
by using Wizard SV Gel and PCR Clean-Up (Promega,
Madison, WI), followed by measurement of DNA concen-
tration by using NanoDrop 2000c spectrophotometer
(Thermo Fisher Scientific, Wilmingdon, DE). 600 ng of
DNA for MSTN targeting TALEN or 200 ng of DNA for
AAVS1 in NEBuffer 2 (New England BioLabs, Ipswich,
MA) was then denatured at 95°C for 10 minutes, and
reannealed slowly using the following temperature pro-
gram to form DNA heteroduplex if NHEJ occurred: 90 cy-
cles of 95-59°C with a 0.4°C decrease per cycle for
20 seconds, 90 cycles of 59 to 32°C with a 0.3°C decrease
per cycle for 20 seconds, and 20 cycles of 32 to 26°C
with a 0.3°C decrease per cycle for 20 seconds. 0.5 uL
T7 Endonuclease I (T7E1; New England BioLabs, Ipswich,
MA) was added to the reannealed DNA samples, followed
by incubation for 30 minutes. DNA samples were then
subjected to electrophoresis on a 2% TAE agarose gel con-
taining Gel-Red (Biotium, Mayward, CA). The gels were
imaged using ChemiDoc XRS + system (Bio-Rad Labora-
tories, Hercules, CA), and densiometry of DNA bands
were quantified using ImageJ software (NIH, Frederick,
MD). Mutation frequencies were calculated using the for-
mula: fractional modification = 1-(1-(total densiometry of
fraction cleaved/total densiometry))0.5 as described [18].
Fluorescence microscopy
Fluorescence and bright-field images were taken as previ-
ously mentioned [13]. In short, images were taken using an
inverted Nikon Ti-E microscope equipped with a Xenon
lamp (Hamamatsu Photonics Systems, Bridgewater, NJ), a 40
× 1.30 NA objective (Nikon, Tokyo, Japan), and an Evolve
512 EMCCD camera (Photometrics, Pleasanton, CA). The
EMCCD camera was cooled to −80°C during imaging. Im-
ages were documented and analyzed using NIS-Elements
Advanced Research software package (Nikon, Tokyo, Japan).
Statistical analysis
All data were expressed as mean ± SEM. Statistical dif-
ferences were determined by unpaired Student’s t-test
for two groups using GraphPad Prism 5.0. Statistical sig-
nificance was defined to be p < 0.05.
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